StockData

Entera Bio vs VivoSim Labs

ENTX and VIVS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ENTX and VIVS compare

Entera Bio is the larger company, worth 1354 times as much as VivoSim Labs ($519M against $384K).

VivoSim Labs grew revenue faster over the last twelve months (−21.1% versus −100% for Entera Bio).

Entera Bio scores higher on the StockData Score (6 against 5 for VivoSim Labs), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricENTXVIVS
Size and price
Market cap$519M$384K
Share price$3.00$0.120
Change, 1 year10.7%−94.5%
Change, 5 years−12.5%−99.8%
Beta (5Y)−0.342.58
Employees2015
StockData Score
Total score6 (better)5
Valuation score01 (better)
Growth score00
Performance score00
Health score6 (better)4
Dividend score00
Valuation
P/S–3.4×
P/B71.5×–
FCF yield−2.1% (better)−2639%
Growth
Revenue growth (TTM)−100%−21.1% (better)
Revenue growth, 5Y average−35.1%–
EPS growth, 5Y average−17.9%–
Profitability
Operating margin–−10117%
Net margin–−11016%
FCF margin–−9038%
Return on equity−139% (better)−343%
Return on invested capital−966%–
Financial health
Debt / equity0.00–
Interest coverage–−944.3×
Current ratio8.98 (better)1.70
Altman Z-score14.32 (better)−139.28
Piotroski F-score3 (better)2
Dividends and buybacks
Buyback yield−0.01% (better)−781%
Shareholder yield−0.01% (better)−781%
Ownership
Held by institutions6.2%3.2%
Held by insiders11.3%–
Insider net buying, 12 months$141K (better)$2.8K
Short interest, % of float4.6%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.